MitoQ

Huma’s $130m raise will scale its digital health platform

Latest articles

A better model organism for testing antiaging drugs?

Harvard researcher proposes the Daphnia water flea as an alternative to worms for building a scalable platform for antiaging drugs research. In many ponds and...

Small is mighty when it comes to mitochondria supplements

Optimise, energise, revitalise – MitoQ is on a mission to supplement your mitochondrial health. Coenzyme Q10 – or CoQ10 – is made naturally in the...

What the aging field needs

Changing the narrative – Celine Halioua reveals why the aging field needs to be taught some new tricks. Celine Halioua is the Founder and CEO...

Insilico Medicine gets $255m boost for AI-powered R&D

Insilico closes $255 million to progress into human clinical trials and develop novel targets and also announces Teva Pharm collaboration. Insilico Medicine, a company driving...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...
fundraising

Editor's picks

A better model organism for testing antiaging drugs?

Harvard researcher proposes the Daphnia water flea as an alternative to worms for building a scalable platform for antiaging drugs research. In many ponds and...

Small is mighty when it comes to mitochondria supplements

Optimise, energise, revitalise – MitoQ is on a mission to supplement your mitochondrial health. Coenzyme Q10 – or CoQ10 – is made naturally in the...

What the aging field needs

Changing the narrative – Celine Halioua reveals why the aging field needs to be taught some new tricks. Celine Halioua is the Founder and CEO...
MitoQ

Click the globe for translations.

With the goal of bringing proactive, predictive care to all, Huma has $130 million financing from leading health and technology companies.

The investment arms of Bayer, Hitachi, Samsung, Sony Innovation Fund by IGV, Unilever and the PE fund HAT are financing Huma Therapeutics Ltd to the tune of approximately $130 million.

Longevity.Technology: This sizeable investment will scale Huma’s modular platform which can power digital ‘hospitals at home’ nationally, and support the pharmaceutical and research industries to run the largest ever decentralised clinical trials. Huma’s platform combines predictive algorithms, digital biomarkers and real-world data to advance proactive care and research and expand their presence globally after last year’s acquisition of AI and wearables companies Biobeat and Tarilian Laser Technologies.

As interventions lead to longer lifespans and an aging population, aging in place continues to gather investment and inform strategy at a government level; Longevity.Technology is preparing a market intelligence report on the sector, and this is available to pre-order.

Leaps by Bayer and Hitachi Ventures led the Huma Series C funding round, which also saw new strategic and financial investors become shareholders. Samsung Next, Sony Innovation Fund by IGV, Unilever Ventures and HAT Technology & Innovation Fund by HAT, as well as individuals Nikesh Arora (former president of SoftBank) and Michael Diekmann (Chairman of Allianz) are also new shareholders.

Huma
Huma’s digital ‘hospital at home’

A further commitment of $70 million that can be exercised at a later date has also been agreed as part of the Series C funding round and takes the total financing raised to more than $200 million. Goldman Sachs International acted as lead placement agent to Huma. HSBC Bank plc and Nomura acted as joint placement agents, with the latter also becoming a shareholder.

 


 

This is a pivotal moment in Huma’s development. We have exceptional partners and strategic investors who will support us in our mission to help people worldwide live longer and fuller lives.”

 


 

The new investment will be used to expand Huma’s digital platform in the US, Asia and the Middle East, with Huma having recently been named Europe’s fastest growing healthcare company by the Financial Times. Huma has an established health technology and innovation partnership with four national governments (England’s NHS, Wales, Germany and UAE). Its digital ‘hospital at home’ was co-created with clinicians and has been independently shown to almost double clinical capacity, reduce hospital readmissions by over a third and has patient adherence levels of over 90%. The service is supporting governments’ pandemic responses on a not-for-profit basis and is now used for a range of patients including those going through knee- and hip-replacement surgery, for example with Smith+Nephew.

Huma
The ‘hospital at home’ mobile app.

Huma advanced its work in the US in 2021, fostering new partnerships with clinical research organisations, health care providers, payers, research organisations and tech companies.

Dan Vahdat, Founder and CEO of Huma, said: This is a pivotal moment in Huma’s development. We have exceptional partners and strategic investors who will support us in our mission to help people worldwide live longer and fuller lives. We’re already demonstrating how ‘hospital at home’ can transform healthcare, and how decentralized clinical trials can advance research in ways that weren’t imaginable even one year ago. Now we want to accelerate the pace of change and continue to innovate for better care and research worldwide [1].’’

Alan Milburn, former UK Health Secretary and Chairman of Huma’s Board, said: “This is a significant moment in Huma’s history and I will work to build enduring, trusted relationships with our new partners. We are living through unprecedented times and the importance of health and well-being is underlined as never before. Together with our partners we can use our expertise, technology, and innovation to change the face of healthcare and research and impact people’s health everywhere [1].”

Huma’s ambition to improve people’s health across the world will be accelerated with its new global partnerships. Juergen Eckhardt, Head of Leaps by Bayer, commented: “Aligned with the vision of Leaps by Bayer, Huma’s expertise and technology will help drive a global paradigm shift towards prevention and care and may boost research efforts using data and digital technology. We invest into the most disruptive technologies of our time that have the potential to change the world for the better. As an early investor into Huma we know how perfectly the company fits into that frame as one of the leading digital innovators in healthcare and lifesciences [1].”

[1] https://info.huma.com/financing-announcement

Images courtesy of Huma

Comment on this article

Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.
MitoQ

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

Spermidine: the mind-enhancing supplement

Scientists are finding that a high intake of dietary spermidine could slow down (or reverse) the brain aging process. Memory loss and slower brain function...
fundraising

Related articles

A better model organism for testing antiaging drugs?

Harvard researcher proposes the Daphnia water flea as an alternative to worms for building a scalable platform for antiaging drugs research. In many ponds and...

Insilico Medicine gets $255m boost for AI-powered R&D

Insilico closes $255 million to progress into human clinical trials and develop novel targets and also announces Teva Pharm collaboration. Insilico Medicine, a company driving...

Longevity focused crypto platform to launch token auction

Lead researcher behind VitaDAO’s first project reveals more about his work and why crypto provides an exciting new funding option for longevity scientists. Later this...

Calling all longevity start-ups and scale-ups

Some news from us! Longevity.Technology's brand-new investment portal brings innovators and investors together. As a part of our mission to support the companies that will...

Occuity – shining a light on health and longevity

Forget windows to the soul, Occuity's non-invasive smart diagnostic tech provides a window to health and wellness. DISCLOSURE: Longevity.Technology (a brand of First Longevity Limited)...
MitoQ